Trial Profile
A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of CCP-020 (Diacerein 1%) Topical Ointment in Healthy Subjects Using a Cumulative Irritant Patch Test Design
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2020
Price :
$35
*
At a glance
- Drugs Diacerein (Primary)
- Indications Bullous pemphigoid; Epidermolysis bullosa; Gout; Joint disorders; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Castle Creek Pharmaceuticals
- 22 Mar 2018 New trial record